Abstract
Realization of part of clinical trial called: A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif(R)) in Patients With Relapsing Multiple Sclerosis